IL327472A - Antibody binds to trbv5-1 segment of human tcr domain - Google Patents

Antibody binds to trbv5-1 segment of human tcr domain

Info

Publication number
IL327472A
IL327472A IL327472A IL32747226A IL327472A IL 327472 A IL327472 A IL 327472A IL 327472 A IL327472 A IL 327472A IL 32747226 A IL32747226 A IL 32747226A IL 327472 A IL327472 A IL 327472A
Authority
IL
Israel
Prior art keywords
trbv5
segment
antibody binds
human tcr
tcr domain
Prior art date
Application number
IL327472A
Other languages
Hebrew (he)
Inventor
Aleksei Vladimirovich Kononov
Stanislav Rudolfovich Evdokimov
Mariia Vladimirovna Zhiriakova
Elena Sergeevna Fetisova
Iana Andreevna Smirnova
Iuliia Viktorovna Evdokimovskaia
Diana Aleksandrovna Kondinskaia
Natalya Viacheslavovna Zhukova
Natalia Aleksandrovna Vereshchagina
Elena Vladislavovna Raznikova
Dmitry Valentinovich Morozov
Original Assignee
Joint Stock Co Biocad
Aleksei Vladimirovich Kononov
Stanislav Rudolfovich Evdokimov
Mariia Vladimirovna Zhiriakova
Elena Sergeevna Fetisova
Iana Andreevna Smirnova
Iuliia Viktorovna Evdokimovskaia
Diana Aleksandrovna Kondinskaia
Natalya Viacheslavovna Zhukova
Natalia Aleksandrovna Vereshchagina
Elena Vladislavovna Raznikova
Dmitry Valentinovich Morozov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2023125460A external-priority patent/RU2023125460A/en
Application filed by Joint Stock Co Biocad, Aleksei Vladimirovich Kononov, Stanislav Rudolfovich Evdokimov, Mariia Vladimirovna Zhiriakova, Elena Sergeevna Fetisova, Iana Andreevna Smirnova, Iuliia Viktorovna Evdokimovskaia, Diana Aleksandrovna Kondinskaia, Natalya Viacheslavovna Zhukova, Natalia Aleksandrovna Vereshchagina, Elena Vladislavovna Raznikova, Dmitry Valentinovich Morozov filed Critical Joint Stock Co Biocad
Publication of IL327472A publication Critical patent/IL327472A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL327472A 2023-10-04 2024-10-04 Antibody binds to trbv5-1 segment of human tcr domain IL327472A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2023125460A RU2023125460A (en) 2023-10-04 A monoclonal antibody or antigen-binding fragment thereof that specifically binds to the TRBV5-1 segment of the variable domain of the beta chain of the human T-cell receptor and its use
PCT/RU2024/050243 WO2025075529A1 (en) 2023-10-04 2024-10-04 Antibody binds to trbv5-1 segment of human tor domain

Publications (1)

Publication Number Publication Date
IL327472A true IL327472A (en) 2026-05-01

Family

ID=95283622

Family Applications (1)

Application Number Title Priority Date Filing Date
IL327472A IL327472A (en) 2023-10-04 2024-10-04 Antibody binds to trbv5-1 segment of human tcr domain

Country Status (4)

Country Link
AU (1) AU2024355291A1 (en)
CO (1) CO2026005258A2 (en)
IL (1) IL327472A (en)
WO (1) WO2025075529A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR117735A1 (en) * 2018-12-25 2021-08-25 Joint Stock Company “Biocad” MONOCLONAL ANTIBODIES THAT SPECIFICALLY BIND TO REGION b OF THE HUMAN T-CELL RECEPTOR FAMILY TRBV-9, AND METHODS FOR ITS USE
US20230108300A1 (en) * 2020-01-29 2023-04-06 The Trustees Of The University Of Pennsylvania Compositions and methods of t cell receptor vb family member targeting for the treatment of t cell associated disease
CN116249718A (en) * 2020-08-26 2023-06-09 马伦戈治疗公司 Multifunctional molecules binding to calreticulin and uses thereof

Also Published As

Publication number Publication date
WO2025075529A1 (en) 2025-04-10
AU2024355291A1 (en) 2026-04-16
WO2025075529A9 (en) 2026-04-16
CO2026005258A2 (en) 2026-05-07

Similar Documents

Publication Publication Date Title
SG11202112951TA (en) Detection of antibodies to sarsr-cov
MX419677B (en) BISPECIFIC ANTI-PSMA X ANTI-CD28 ANTIBODIES AND THEIR USES
EP3657922A4 (en) COMPOSITION OF ABSORPTION OF ELECTROMAGNETIC WAVES AND ABSORPTION BODY OF ELECTROMAGNETIC WAVES
PT2158217E (en) NEUTRALIZING HUMAN MONOCLONAL ANTIBODY OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR AND ITS USE
IL284367A (en) Monoclonal antibodies that uniquely bind to human TRBV9
IL281022A (en) Treatment of NSCLC patients resistant to anti-PD-1 antibody
IL287385A (en) Use of anti-cd19 antibody to treat autoimmune disease
MX2021003673A (en) HUMAN ANTI-VSIG4 ANTIBODIES AND THEIR USES.
IL277211A (en) Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor
EP3746123A4 (en) ANTIBODIES TO GALECTIN-3 AND METHOD OF USING THEREOF
IL277375A (en) Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
IL316065A (en) Anti-cd28 antibodies and methods of use thereof
EP4464337A4 (en) COMBINED USE OF AN ANTI-TROP-2 ANTIBODIE CONJUGATE AND OTHER THERAPEUTICS
EP3668297A4 (en) COMPOSITION OF ABSORPTION OF ELECTROMAGNETIC WAVES AND ABSORPTION BODY OF ELECTROMAGNETIC WAVES
CA3307212A1 (en) Antibody binds to trbv5-1 segment of human tcr domain
IL311234A (en) New combinations of antibodies and their uses
EP4365202A4 (en) ANTI-TROP2 SINGLE DOMAIN ANTIBODIES AND USE THEREOF
IL306128A (en) Human antibodies to artemin and methods of use thereof
EP4188432A4 (en) ANTIBODY SPECIFIC TO MUCIN-1 AND METHODS OF USE THEREOF
UA110051C2 (en) Normal;heading 1;heading 2;heading 3;ANTIBODY THAT BINDS TGF-ALPHA AND EPIREGULIN
CA3257922A1 (en) Use of anti-claudin-1 antibodies to treat cholangiopathies
HRP20260266T1 (en) DOSAGE FORMS FOR TOPICAL APPLICATION OF PENTACYCLIC TRITERPENES
IL308296A (en) Use of an anti-cd19 antibody to treat myasthenia gravis
GB202008958D0 (en) Antibodies specific to domain D of tenascin C
GB202005540D0 (en) Antibodies specific to domain D of tenascin C